Compare KKR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KKR | SNY |
|---|---|---|
| Founded | 1976 | 1994 |
| Country | United States | France |
| Employees | 4200 | 74846 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.1B | 104.5B |
| IPO Year | N/A | N/A |
| Metric | KKR | SNY |
|---|---|---|
| Price | $102.81 | $43.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $132.85 | $58.00 |
| AVG Volume (30 Days) | ★ 3.9M | 3.2M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | 0.75% | ★ 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.49 |
| Revenue Next Year | $25.41 | $6.10 |
| P/E Ratio | $44.27 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $82.67 | $40.89 |
| 52 Week High | $152.10 | $52.68 |
| Indicator | KKR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 46.06 |
| Support Level | $97.40 | $42.64 |
| Resistance Level | $105.99 | $45.22 |
| Average True Range (ATR) | 3.63 | 0.76 |
| MACD | 0.56 | -0.15 |
| Stochastic Oscillator | 59.52 | 34.63 |
KKR is one of the world's largest alternative asset managers, with $723.2 billion in total managed assets, including $585.0 billion in fee-earning AUM, at the end of September 2025. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.